top of page
Arise home horizontal portrait.jpg

SCIENCE COMMERCIALISATION

What will break your deep tech commercialisation?

The technology shows promise. But is there a viable route to market for it? What should be done next and who contributes how? I stress-test the commercial case and show you what’s supported, what’s missing and how to cut through noise.

FOR PORTFOLIOS

Deep tech strategy de-risking

 

Several technologies look promising.

 

See which fit your portfolio now and where a closer look could change the decision.

FOR PROGRAMME FUNDERS & LEADERS

Programme evaluation & design

 

Your cohort hit its targets. What changed?

 

Find what you contributed to progress and where to change the design before the next reporting.

Where do you need a second pair of eyes?

Is this worth a closer look? → First assessment

Where could our plan break? → Second opinion or red team

What should happen first? → Commercial strategy or programme design

The buyer is interested. Why aren’t they moving?

A buyer likes the technology but won’t act on lab data alone. Before paying for another test, the transfer team asks what result, under which operating conditions, would let the buyer move forward.

THE CHECK

Would this happen without your support?

 

If the team could reach the same buyer on its own, look for the obstacle your organisation is better placed to remove.

Start by asking who can act on the evidence, and what they would do next.

Four linked steps in a deep tech example: a buyer needs usable proof, a transfer team brings the buyer in, the buyer defines what counts, and the team can plan its next test.

BEFORE
A promising technology.
An unclear next step.

Several routes look plausible. Which one could a buyer or delivery partner actually act on?

AFTER THE WORK
A clearer next step,
with conditions.

A condition to test, a stakeholder who can help, and a signal for whether to continue.

What should you test before you scale?

Maria Ksenia Witte — scientist and independent science commercialisation adviser for deep tech ventures and portfolios.

Who you’ll work with

Hi, I'm Maria Ksenia Witte

You work directly with me: a scientist and independent commercialisation expert. I will challenge the assumptions, explain my judgement and tell you what would change it. You get a clear position — and the evidence to defend your next move.

 

250+ cases assessed · 25+ programmes & ecosystems

€120M+ allocation exposure

 

My QUATISE® methodology is built on formally certified applied RD&I under OECD Frascati criteria (validated through the German Federal Ministry of Research, Technology and Space).

Newsletter
Briefs

Analysis of the decisions connecting science, commercialisation, capital and policy.

Each brief examines a consequential question, the evidence behind it and what it could change about the next move.

bottom of page